Sdrol, unlike Adrol, Var, Dbol, is both a strong and potent AR ligand. Rather than exerting myotrophy primarily (I believe, working hypothesis) by modulating glucocorticoids like the other popular orals, it does exert a direct anabolism via the AR, likely directly increasing mIGF-I activity. It's also possible (Schanzer view) that, for example, Adrol's metabolites are stronger ligands than the parent oxymetholone and exert direct AR agonism/potency. I find it compelling that it's been so many years since this was hypothesized, yet no direct evidence of these metabolites functioning directly via AR agonism exists; and the bulk of the literature shows non-AR-mediated mechanisms for many of the popular orals.